Bevacizumab and breast cancer: A meta-analysis of first-line phase III studies and a critical reappraisal of available evidence

Journal of Oncology

Volumn , Issue , 2012, Pages

  Rossari, José R ^a   Metzger Filho, Otto ^a   Paesmans, Marianne ^a   Saini, Kamal S ^a   Gennari, Alessandra ^b   De Azambuja, Evandro ^a   Piccart Gebhart, Martine ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b GALLIERA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; PACLITAXEL; PLACEBO; TAXANE DERIVATIVE;

ADULT; ARTICLE; BREAST CANCER; BREAST METASTASIS; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EVIDENCE BASED PRACTICE; FEMALE; HAZARD RATIO; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; META ANALYSIS; META ANALYSIS (TOPIC); OVERALL RESPONSE RATE; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TREATMENT RESPONSE;

EID: 84867338601     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2012/417673     Document Type: Article

References (37)

1. Banerjee S., Dowsett M., Ashworth A., Martin L.-A., Mechanisms of Disease: angiogenesis and the management of breast cancer. Nature Clinical Practice Oncology 2007 4 9 536 550 2-s2.0-34548462626 10.1038/ncponc0905 (Pubitemid 47351464)
2. Aghajanian C., Finkler N. J., Rutherford T., OCEANS: a randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). Journal of Clinical Oncology 2011 29 supplement 18. Abstract no. LBA5007
3. Sandler A., Gray R., Perry M. C., Brahmer J., Schiller J. H., Dowlati A., Lilenbaum R., Johnson D. H., Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. The New England Journal of Medicine 2006 355 24 2542 2550 2-s2.0-33845490014 10.1056/NEJMoa061884 (Pubitemid 44917502)
4. Escudier B., Pluzanska A., Koralewski P., Ravaud A., Bracarda S., Szczylik C., Chevreau C., Filipek M., Melichar B., Bajetta E., Gorbunova V., Bay J. O., Bodrogi I., Jagiello-Gruszfeld A., Moore N., Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. The Lancet 2007 370 9605 2103 2111 2-s2.0-37349080670 10.1016/S0140-6736(07)61904-7 (Pubitemid 350296300)
5. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R., Kabbinavar F., Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. The New England Journal of Medicine 2004 350 23 2335 2342 2-s2.0-2542561964 10.1056/NEJMoa032691 (Pubitemid 38702844)
6. Hurwitz H. I., Fehrenbacher L., Hainsworth J. D., Heim W., Berlin J., Holmgren E., Hambleton J., Novotny W. F., Kabbinavar F., Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. Journal of Clinical Oncology 2005 23 15 3502 3508 2-s2.0-20644432867 10.1200/JCO.2005.10.017
7. Kristensen G., Perren T., Qian W., Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. Journal of Clinical Oncology 2011 29 18, supplement. Abstract no. LBA5006
8. Kreisl T. N., Kim L., Moore K., Duic P., Royce C., Stroud I., Garren N., Mackey M., Butman J. A., Camphausen K., Park J., Albert P. S., Fine H. A., Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. Journal of Clinical Oncology 2009 27 5 740 745 2-s2.0-59949083263 10.1200/JCO.2008.16.3055
9. Allison M., Avastin's commercial march suffers setback. Nature Biotechnology 2010 28 9 879 880 2-s2.0-77956666250 10.1038/nbt0910-879
10. Montero A. J., Vogel C., Fighting fire with fire: rekindling the bevacizumab debate. The New England Journal of Medicine 2012 366 4 374 375 2-s2.0-84856263234 10.1056/NEJMe1113368
11. Miller K., Wang M., Gralow J., Dickler M., Cobleigh M., Perez E. A., Shenkier T., Cella D., Davidson N. E., Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. The New England Journal of Medicine 2007 357 26 2666 2676 2-s2.0-37549040613 10.1056/NEJMoa072113
12. Miles D. W., Chan A., Dirix L. Y., Cortés J., Pivot X., Tomczak P., Delozier T., Sohn J. H., Provencher L., Puglisi F., Harbeck N., Steger G. G., Schneeweiss A., Wardley A. M., Chlistalla A., Romieu G., Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. Journal of Clinical Oncology 2010 28 20 3239 3247 2-s2.0-77954700380 10.1200/JCO.2008.21.6457
13. Robert N. J., Dieras V., Glaspy J., RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). Journal of Clinical Oncology 27 supplement, article 15s. Abstract no. 1005
14. Moher D., Liberati A., Tetzlaff J., Altman D. G., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009 339, article b2535 2-s2.0-68549135227 10.1136/bmj.b2535
15. Parmar M. K., Torri V., Stewart L., Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998 17 24 2815 2834 (Pubitemid 28562978)
16. Higgins J. P. T., Thompson S. G., Deeks J. J., Altman D. G., Measuring inconsistency in meta-analyses. BMJ 2003 327 7414 557 560 2-s2.0-0041876133 (Pubitemid 37088507)
17. Whitehead A., Meta-Analysis of Controlled Clinical Trials 2002 Chichester, UK Wiley
18. Hapani S., Chu D., Wu S., Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. The Lancet Oncology 2009 10 6 559 568 2-s2.0-66149121478 10.1016/S1470-2045(09)70112-3
19. Valachis A., Polyzos N. P., Patsopoulos N. A., Georgoulias V., Mavroudis D., Mauri D., Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials. Breast Cancer Research and Treatment 2010 122 1 1 7 2-s2.0-73449097493 10.1007/s10549-009-0727-0
20. Lee J. B., Woo O. H., Park K. H., Woo S. U., Yang D. S., Kim A. R., Lee E. S., Kim Y. H., Kim J. S., Seo J. H., Bevacizumab for salvage treatment of metastatic breast cancer: a systemic review and meta-analysis of randomized controlled trials. Investigational New Drugs 2011 29 1 182 188 2-s2.0-79251514639 10.1007/s10637-009-9310-0
21. O'Shaughnessy J., A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). Journal of Clinical Oncology 2010 28, article 15s. abstract no. 1005
22. Cuppone F., Bria E., Vaccaro V., Puglisi F., Fabi A., Sperduti I., Carlini P., Milella M., Nisticò C., Russillo M., Papaldo P., Ferretti G., Aapro M., Giannarelli D., Cognetti F., Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: meta-regression analysis of randomized trials. Journal of Experimental and Clinical Cancer Research 2011 30 1, article 54 2-s2.0-79955845678 10.1186/1756-9966-30-54
23. O'Shaughnessy J., Dieras V., Glaspy J., Comparison of subgroup analyses of PFS from three phase III studies of bevacizumab in combination with chemotherapy in patients with HER2-negative Metastatic Breast Cancer (MBC). Cancer Research 2009 69, article 24s. abstract no. 207
24. Burzykowski T., Buyse M., Piccart-Gebhart M. J., Sledge G., Carmichael J., Lück H. J., Mackey J. R., Nabholtz J. M., Paridaens R., Biganzoli L., Jassem J., Bontenbal M., Bonneterre J., Chan S., Basaran G. A., Therasse P., Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. Journal of Clinical Oncology 2008 26 12 1987 1992 2-s2.0-42949145995 10.1200/JCO.2007.10.8407
25. Miller K. D., Chap L. I., Holmes F. A., Cobleigh M. A., Marcom P. K., Fehrenbacher L., Dickler M., Overmoyer B. A., Reimann J. D., Sing A. P., Langmuir V., Rugo H. S., Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. Journal of Clinical Oncology 2005 23 4 792 799 2-s2.0-20044364346 10.1200/JCO.2005.05.098 (Pubitemid 46224178)
26. Brufsky A. B. I., Smirnov V., Hurvitz S., Perez E., Ponomarova O., Vynnychenko I., Swamy R., Mu H., Rivera R., RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab In combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer. Cancer Research 2009 69 supplement, article 24. Abstract no. 42
27. Bear H. D., Tang G., Rastogi P., Geyer C. E. Jr., Robidoux A., Atkins J. N., Baez-Diaz L., Brufsky A. M., Mehta R. S., Fehrenbacher L., Young J. A., Senecal F. M., Gaur R., Margolese R. G., Adams P. T., Gross H. M., Costantino J. P., Swain S. M., Mamounas E. P., Wolmark N., Bevacizumab added to neoadjuvant chemotherapy for breast cancer. The New England Journal of Medicine 2012 366 4 310 320 2-s2.0-84856253589 10.1056/NEJMoa1111097
28. Von Minckwitz G., Eidtmann H., Rezai M., Fasching P. A., Tesch H., Eggemann H., Schrader I., Kittel K., Hanusch C., Kreienberg R., Solbach C., Gerber B., Jackisch C., Kunz G., Blohmer J.-U., Huober J., Hauschild M., Fehm T., Müller B. M., Denkert C., Loibl S., Nekljudova V., Untch M., Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. The New England Journal of Medicine 2012 366 4 299 309 2-s2.0-84856291930 10.1056/NEJMoa1111065
29. Cortes J., Calvo V., Ramírez-Merino N., Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. Annals of Oncology 2011 23 5 1130 1137
30. An M. M., Zou Z., Shen H., Liu P., Chen M. L., Cao Y. B., Jiang Y. Y., Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis. European Journal of Clinical Pharmacology 2010 66 8 813 821 2-s2.0-77955523015 10.1007/s00228-010-0815-4
31. Nalluri S. R., Chu D., Keresztes R., Zhu X., Wu S., Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008 300 19 2277 2285 2-s2.0-56649123212 10.1001/jama.2008.656
32. Schutz F. A. B., Je Y., Azzi G. R., Nguyen P. L., Choueiri T. K., Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Annals of Oncology 2011 22 6 1404 1412 2-s2.0-79957790694 10.1093/annonc/mdq587
33. Choueiri T. K., Mayer E. L., Je Y., Rosenberg J. E., Nguyen P. L., Azzi G. R., Bellmunt J., Burstein H. J., Schutz F. A. B., Congestive heart failure risk in patients with breast cancer treated with bevacizumab. Journal of Clinical Oncology 2011 29 6 632 638 2-s2.0-79952083872 10.1200/JCO.2010.31.9129
34. Ranpura V., Hapani S., Wu S., Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 2011 305 5 487 494 2-s2.0-79551520348 10.1001/jama.2011.51
35. Smith I. E., Pierga J. Y., Biganzoli L., Cortés-Funes H., Thomssen C., Pivot X., Fabi A., Xu B., Stroyakovskiy D., Franke F. A., Kaufman B., Mainwaring P., Pienkowski T., de Valk B., Kwong A., González-Trujillo J. L., Koza I., Petrakova K., Pereira D., Pritchard K. I., First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients. Annals of Oncology 2011 22 3 595 602 2-s2.0-79952027747 10.1093/annonc/mdq430
36. Burstein H. J., Bevacizumab for advanced breast cancer: all tied up with a RIBBON? Journal of Clinical Oncology 2011 29 10 1232 1235 2-s2.0-79953848263 10.1200/JCO.2010.33.2684
37. Dienstmann R., Ades F., Saini K. S., Benefit-risk assessment of bevacizumab in the treatment of breast cancer. Drug Safety 2012 35 1 15 25